Inogen, Inc. — FY2022 Form 10-K
Reporting period: Year ended December 31, 2022. This is an annual filing; the supplied text does not provide standalone fourth-quarter results. Amounts below are in U.S. dollars.
Business context
Inogen develops, manufactures, sells and rents portable oxygen concentrators and related products. It operates in the United States and sells in 59 countries. The company reported 1,026 employees at year-end and is shifting toward a respiratory medical-device model while continuing U.S. home medical equipment operations, including direct-to-consumer sales and rentals.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Total revenue | $377.2 million | $358.0 million |
| Sales revenue | $320.5 million | $311.7 million |
| Rental revenue | $56.7 million | $46.3 million |
| Gross profit / margin | $153.5 million / 40.7% | $176.5 million / 49.3% |
| Operating income (loss) | $(85.2) million | $9.2 million |
| Net income (loss) | $(83.8) million | $(6.3) million |
| Net loss per diluted share | $(3.67) | $(0.28) |
| Operating cash flow | $(37.5) million | $23.6 million |
| Cash and cash equivalents at year-end | $187.0 million | $235.5 million |
| Net working capital | $239.3 million | $267.7 million |
- Sales gross margin fell to 38.3% from 48.1%; rental gross margin declined to 54.3% from 57.4%.
- Capital expenditures and rental-equipment investment totaled $21.2 million in 2022, including $17.9 million for rental equipment.
- The balance sheet reports no borrowings; it includes $23.3 million of operating lease liabilities. Purchase obligations were $109.9 million, due within one year.
- Current assets were $304.6 million against current liabilities of $65.3 million. Management said cash and expected cash generation should cover projected operating and investing requirements for at least 12 months.
- Non-GAAP Adjusted EBITDA was a loss of $13.5 million, versus positive Adjusted EBITDA of $29.5 million in 2021.
Material changes versus FY2021
- Revenue increased 5.4%, led by rental revenue growth of 22.5% and international business-to-business sales growth of 27.3%. Domestic direct-to-consumer sales fell 5.4%; domestic business-to-business sales fell 5.8%.
- Systems sold declined about 3%, to approximately 170,500 from 175,800, with supply constraints cited as a key factor.
- Gross profit decreased $23.0 million as costs rose faster than revenue. Semiconductor-chip purchases on the open market added $23.8 million in material costs; unfavorable channel mix, warranty costs, labor and overhead also pressured margins.
- Operating cash flow swung from positive $23.6 million to negative $37.5 million, including a $51.3 million increase in accounts receivable. Cash declined by $48.5 million during the year.
- Net loss included a $52.2 million noncash loss on disposal of New Aera’s TAV technology assets. The company stopped developing and abandoned the program in December 2022, citing limited commercial prospects, lack of compatibility, reimbursement and litigation issues, and substantial additional investment needs.
Outlook, risks and unusual items
- No formal revenue or earnings guidance is stated in the supplied filing text. Management expects rental revenue to grow as it expands prescriber sales, rental setups and insurance contracts; it also expected a return to normalized demand in the first half of 2023.
- Management expects semiconductor availability and cost pressures, inflation in other components, labor and wage pressures, and possible supply-chain disruption to continue into 2023. A six-week production suspension at U.S. sites and the Czech contract manufacturer occurred in early 2022 because of chip shortages.
- European product availability was affected by delayed EU Medical Device Regulation certification. Certification for the G4 and Rove 6, including an updated G5 version, was issued in December 2022. Rove 6 launched in Europe in December; Rove 4 received FDA 510(k) clearance in December and was planned for U.S. launch in 2023.
- Reimbursement is a material risk: Medicare’s traditional fee-for-service programs represented 77.0% of rental revenue in 2022. Management noted uncertainty around post-public-health-emergency payment rules, future competitive bidding and coverage determinations. The filing states that the public health emergency was scheduled to expire May 11, 2023.
- A U.S. Attorney’s Office civil investigative demand received in June 2022 concerns a False Claims Act investigation into possible kickbacks involving portable oxygen concentrator manufacturers. The inquiry includes customer financing, guarantees and a customer agreement with marketing, exclusivity, discount and financing terms. Inogen is cooperating; outcome and potential liability are undetermined.
- Other key exposures include customer and supplier concentration, two customers representing more than 10% each of year-end accounts receivable, reliance on single-source components, foreign-exchange movements, product liability and healthcare regulatory compliance. The company had $109.9 million of purchase orders outstanding at year-end.
- The company recorded a $41.9 million valuation allowance against deferred tax assets at year-end, citing cumulative losses and projected future taxable losses. Deloitte issued unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Whether gross margins and operating cash flow recover as semiconductor costs, supply availability and channel mix change.
- Collections and payment terms for the two large customer receivables, and the related credit-insurance coverage and exposure.
- The outcome and potential financial or operational consequences of the federal investigation.
- Actual Medicare reimbursement, coverage and rental-patient trends after the public health emergency and under subsequent CMS policy.
- U.S. launch timing and commercial adoption of Rove 4, and sales and margins for recently certified European products.
- Whether the TAV abandonment has any further financial, legal or contingent effects beyond the recorded disposal loss and reversal of the earnout liability.